Meeting
2024 ASCO Annual Meeting
Pre-clinical modeling of navtemadlin pharmacokinetics (PK), pharmacodynamics (PD), and efficacy in glioblastoma, IDH-wildtype.
Presenter
Rachael A Vaubel, PhD
Mayo Clinic
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Clinical Science Symposium
Session Title
Advancing Trial Design: Illuminating Tumor Evolution in Central Nervous System Cancer
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2012)
DOI
10.1200/JCO.2024.42.16_suppl.2012
Abstract #
2012
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Videos & Slides
2022 ASCO Annual Meeting
Phase I clinical trial to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of NY-ESO-1–specific TCR T-cells (TAEST16001) in HLA-A*02:01 patients with advanced soft tissue sarcoma.
Speaker: Xing Zhang
Videos & Slides
2022 ASCO Annual Meeting
Tumor Tissue and Blood-Based Pharmacokinetic and Pharmacodynamic Evaluations of Signal Transduction Inhibitors in Glioblastoma
Speaker: Nader Sanai, MD
Videos & Slides
2021 ASCO Annual Meeting
Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer.
Speaker: Francisco Robert, MD, FACP